Only the inhibitor TVB-2640 is being currently tested in clinical trials for HER2+ advanced breast cancer, high grade astrocytoma and colon cancer (NCT03179904, NCT03032484, NCT02980029, respectively). Here, ERBB2 is linked to breast carcinoma.